S247: ADDING RUXOLITINIB AND DECITABINE TO BU/CY CONDITIONING REGIMENS TO PROPHYLAXIS POST-TRANSPLANT RELAPSE IN HIGH-RISK AML IS SAFE AND EFFECTIVE: A PROSPECTIVE, PHASE II STUDY

• Yujun Wei,
• Kun Qian,
• Lili Wang,
• Fei LI,
• Nan Wang,
• Bo Peng,
• Yanan Wen,
• Lu Wang,
• Lingmin Xu,
• Xiangshu Jin,
• Liping Dou,
• Dai-Hong Liu

Affiliations

Yujun Wei

1 The Fifth Medical Center of Chinese PLA General Hospital, Department of Hematology, Beijing, China

Kun Qian

1 The Fifth Medical Center of Chinese PLA General Hospital, Department of Hematology, Beijing, China

Lili Wang

3 The First Medical Center of Chinese PLA General Hospital, Department of Hematology, Beijing, China

Fei LI

3 The First Medical Center of Chinese PLA General Hospital, Department of Hematology, Beijing, China

Nan Wang

3 The First Medical Center of Chinese PLA General Hospital, Department of Hematology, Beijing, China

Bo Peng

1 The Fifth Medical Center of Chinese PLA General Hospital, Department of Hematology, Beijing, China

Yanan Wen

3 The First Medical Center of Chinese PLA General Hospital, Department of Hematology, Beijing, China

Lu Wang

3 The First Medical Center of Chinese PLA General Hospital, Department of Hematology, Beijing, China

Lingmin Xu

3 The First Medical Center of Chinese PLA General Hospital, Department of Hematology, Beijing, China

Xiangshu Jin

3 The First Medical Center of Chinese PLA General Hospital, Department of Hematology, Beijing, China

Liping Dou

3 The First Medical Center of Chinese PLA General Hospital, Department of Hematology, Beijing, China

Dai-Hong Liu

1 The Fifth Medical Center of Chinese PLA General Hospital, Department of Hematology, Beijing, China